ZIOP - Earnings announcements

HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "I am impressed by the quality and dedication of our team at Ziopharm who all are diligently working to transform our cutting-edge scientific research into meaningful clinical progress. Last quarter we made the decision to restructure the organization and focus our efforts on advancing our differentiated TCR-T library towards the clinic," said Kevin S. Boyle, Sr., Chief Executive Officer at Ziopharm Oncology. "We are making excellent progress to operationa

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results. The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at w

Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele Baffa MD, Ph.D. appointed Head of Research and Development in addition to Chief Medical Officer Adam Levy, Ph.D., MBA appointed Executive Vice President, Corporate Development and Investor Relations Conference call scheduled for today at 4:30 pm EDT BOSTON and HOUSTON, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the appointment of Kevin S. Boyl

Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company's manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank, strengthening balance sheet and extending cash runway into the fourth quarter of 2022 Provided update on CD19 RPM CAR-T trial being conducted by Eden BioCell Conference call scheduled for today at 4:30 pm EDT BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today provided corporate updates for the second quarter of 2021, ended June 30, 2021. The Company will host a conference call and webcast toda

BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021. The conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or 201-389-0879 (International). The passcode for the conference call is 13721210. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company's website for approximately 90 days aft

– Annual shareholder meeting planned for May 19, 2021 – Company to host conference call today at 4:30 pm ET BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced its financial results for the first quarter ended March 31, 2021 and provided additional corporate updates. The Company will host a conference call and webcast today at 4:30 pm ET. Recent Corporate Highlights and Updates Announced that the infusion of the first patient in the CD19-Specific Rapid Personalized Manufacturing (RPM) CAR-T Phase I Clinical Trial being conducted in Taiwan by the Company's Joint Venture partner, Eden BioCell, occurred in March.P

Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role James Huang Appointed Executive Chairman and Board Refreshment Completed FDA IND Clearance Announced for Groundbreaking Library TCR-T Phase I/II Clinical Trial, Targeting Six “Hotspot” Mutations in KRAS and TP53 Further Details Provided on R&D Day on March 11 Including Participation of Dr. Steven Rosenberg, Dr. Carl June, and Dr. Scott Kopetz BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial re